Drug
Cyclophosphamide clinical trials
Also written Cytoxan, Neosar, Cytophosphane and WR-138719.
- studies test it
- 1,616
- open now
- 256
- in phase 3
- 200
- first study started
- 1990
Keep track of what changes. Save the Cyclophosphamide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Cyclophosphamide
- 1,319
- CTX
- 237
Brand
- Cytoxan
- 571
- Neosar
- 225
- Revimmune
- 147
- Cycloblastin
- 134
- Cyclostin
- 128
- Cytophosphan
- 127
- Endoxan
- 113
- Procytox
- 22
Other names
Combined with it in one product
- CHOP
- 17
Studies by the year they started
1,604 studies that test it; most in 2017 (81); 4 more planned to start later
| Year | Studies |
|---|---|
| 1990 | 4 |
| 1991 | 8 |
| 1992 | 5 |
| 1993 | 9 |
| 1994 | 10 |
| 1995 | 14 |
| 1996 | 21 |
| 1997 | 14 |
| 1998 | 33 |
| 1999 | 36 |
| 2000 | 32 |
| 2001 | 29 |
| 2002 | 43 |
| 2003 | 38 |
| 2004 | 45 |
| 2005 | 59 |
| 2006 | 62 |
| 2007 | 69 |
| 2008 | 63 |
| 2009 | 57 |
| 2010 | 58 |
| 2011 | 52 |
| 2012 | 44 |
| 2013 | 59 |
| 2014 | 59 |
| 2015 | 74 |
| 2016 | 57 |
| 2017 | 81 |
| 2018 | 62 |
| 2019 | 57 |
| 2020 | 47 |
| 2021 | 56 |
| 2022 | 50 |
| 2023 | 64 |
| 2024 | 34 |
| 2025 | 46 |
| 2026 | 53 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 42
- Phase 1
- 495
- Phase 2
- 997
- Phase 3
- 200
- Phase 4
- 32
- No phase
- 82
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 153 · Other 1,463
M.D. Anderson Cancer Center (74) · National Cancer Institute (NCI) (72) · Fred Hutchinson Cancer Center (53) · Children's Oncology Group (51) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (50) · Memorial Sloan Kettering Cancer Center (45) · St. Jude Children's Research Hospital (45) · City of Hope Medical Center (38)
Often tested with
Tested in the same studies.
Fludarabine (405) · Doxorubicin (279) · Etoposide (204) · Vincristine (204) · Rituximab (163) · Prednisone (152) · Dexamethasone (140) · Methotrexate (121)
Studies
Open first, then newest update. How each study uses Cyclophosphamide is read from its arms, and is right about nine times in ten.
Testing it · 1,616
- Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07524530Written as Cyclophosphamide
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingPhase 3National Cancer Institute (NCI)NCT05675410Written as Cyclophosphamide
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingPhase 1National Cancer Institute (NCI)NCT06904066Written as cyclophosphamide
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06058377Written as Cyclophosphamide
- Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaRecruitingPhase 2University of WashingtonNCT07097363Written as Cyclophosphamide
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)RecruitingPhase 2Fred Hutchinson Cancer CenterNCT03970096Written as Cyclophosphamide
- T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerRecruitingPhase 2National Cancer Institute (NCI)NCT02133196Written as Cyclophosphamide
- T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon CancerRecruitingPhase 1Fred Hutchinson Cancer CenterNCT06043713Written as Cyclophosphamide
- Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALLRecruitingPhase 2/3Bambino Gesù Hospital and Research InstituteNCT07297914Written as Cyclophosphamide
- GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor MalignanciesRecruitingPhase 1National Cancer Institute (NCI)NCT05003895Written as Cyclophosphamide
- Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic MalignanciesRecruitingPhase 1/2National Cancer Institute (NCI)NCT05327023Written as Cyclophosphamide
- Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingPhase 1/2National Cancer Institute (NCI)NCT02830724Written as Cyclophosphamide
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell TransplantationRecruitingPhase 1/2National Cancer Institute (NCI)NCT05436418Written as Cyclophosphamide
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 MutationsRecruitingPhase 2National Cancer Institute (NCI)NCT01861106Written as Cyclophosphamide (CTX, Cytoxan)
- Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic MalignanciesRecruitingPhase 1/2National Cancer Institute (NCI)NCT04959175Written as Cyclophosphamide
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT04002947Written as CHOP
- A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) SyndromeRecruitingPhase 2National Cancer Institute (NCI)NCT05027945Written as Cyclophosphamide (CY)
- FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory RhabdomyosarcomaRecruitingPhase 1National Cancer Institute (NCI)NCT06865664Written as cyclophosphamide
- Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell TransplantationRecruitingPhase 1National Cancer Institute (NCI)NCT07162038Written as Cyclophosphamide
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingPhase 2SWOG Cancer Research NetworkNCT05633615Written as Cyclophosphamide
See all 1,616 studies that test Cyclophosphamide →
Given in every arm · 1,387 — Cyclophosphamide is usual care beside what is tested
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT06124157Written as Cyclophosphamide
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingPhase 2National Cancer Institute (NCI)NCT01174121Written as Cyclophosphamide
- Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 1National Cancer Institute (NCI)NCT07572136Written as Cyclophosphamide
- IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT07672483Written as Cyclophosphamide
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyRecruitingPhase 2University of Michigan Rogel Cancer CenterNCT07892027Written as Cyclophosphamide
- Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related DiseasesRecruitingPhase 1Kite, A Gilead CompanyNCT06626919Written as Cyclophosphamide
- CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT07328503Written as Cyclophosphamide
- GLORY: Glofit-GemOx With Liso-Cel For LymphomaRecruitingPhase 2Massachusetts General HospitalNCT07711483Written as Lymphodepleting chemotherapy
- Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten WorseRecruitingPhase 1/2National Cancer Institute (NCI)NCT07437963Written as Cyclophosphamide
- A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Kite, A Gilead CompanyNCT07887672Written as Cyclophosphamide
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as Cyclophosphamide
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaRecruitingPhase 3National Cancer Institute (NCI)NCT06172296Written as Cyclophosphamide
- CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)RecruitingPhase 1CERo Therapeutics Holdings, Inc.NCT06834282Written as Cyclophosphamide
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06717347Written as Cyclophosphamide
- A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).RecruitingPhase 3AstraZenecaNCT07735637Written as Cyclophosphamide
- Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory DiseaseRecruitingPhase 1National Cancer Institute (NCI)NCT07509034Written as Cyclophosphamide
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT03150693Written as Cyclophosphamide
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of ImmunityRecruitingPhase 2National Cancer Institute (NCI)NCT04339777Written as Cyclophosphamide (Cytoxan)
- Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesRecruitingPhase 2Fred Hutchinson Cancer CenterNCT07228624Written as Cyclophosphamide
- Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual TreatmentRecruitingPhase 1Kite, A Gilead CompanyNCT07304154Written as Cyclophosphamide
Showing 20 of 1,387.
As the comparator · 121 — what is tested is compared with Cyclophosphamide
- A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)RecruitingPhase 3Incyte CorporationNCT06615050Written as Cyclophosphamide
- Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.RecruitingPhase 2Swiss Cancer InstituteNCT07593482Written as Cyclophosphamide
- Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS TumorsRecruitingPhase 2Medical University of ViennaNCT01356290Written as Cyclophosphamide
- Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell TransplantationRecruitingPhase 2University of NebraskaNCT06799195Written as High-dose Cyclophosphamide
- A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaRecruitingPhase 3Regeneron PharmaceuticalsNCT06091254Written as Cyclophosphamide
- TCb vs EC-T in High Risk ER+/HER2- Breast CancerRecruitingPhase 3Fudan UniversityNCT05901428Written as Cyclophosphamide
- Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney FailureRecruitingPhase 2Eastern Cooperative Oncology GroupNCT07085728Written as Cyclophosphamide
- Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) AmyloidosisNot yet recruitingPhase 3AbbVieNCT07793422Written as Cyclophosphamide
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular LymphomaNot yet recruitingPhase 3Ruijin HospitalNCT07719855Written as Cyclophosphamide
- Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in ChildrenNot yet recruitingNot applicableNanfang Hospital, Southern Medical UniversityNCT07675291Written as Cyclophosphamide
- A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)RecruitingPhase 3CelgeneNCT06911502Written as Cyclophosphamide
- Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapyRecruitingPhase 2University of BirminghamNCT05848765Written as Cyclophosphamide
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung DiseaseRecruitingPhase 4Tongji HospitalNCT07077486Written as Cyclophosphamide (CYC)
- Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer (EBC)RecruitingPhase 2Hebei Medical University Fourth HospitalNCT06107673Written as Cyclophosphamide injection
- Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for LymphomaRecruitingPhase 3The Affiliated People's Hospital of Ningbo UniversityNCT06520163Written as CHOP
- Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT05929768Written as Cyclophosphamide
- Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerRecruitingPhase 2Karolinska University HospitalNCT05900206Written as Cyclophosphamide
- Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II TrialRecruitingPhase 2Fei LiNCT06700798Written as Cyclophosphamide
- Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3ANot yet recruitingPhase 2Sun Yat-sen UniversityNCT06961500Written as CHOP
- Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALLRecruitingPhase 3First Affiliated Hospital of Zhejiang UniversityNCT06361329Written as cyclophosphamide
Showing 20 of 121.
Codes
What other systems call Cyclophosphamide · ClinicalTrials.gg INT007282
- MeSH (NLM) D003520CyclophosphamideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 8N3DW7272PCYCLOPHOSPHAMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 3002One source FDA
- Wikidata Q27106287cyclophosphamide hydrateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C405CyclophosphamideOne source FDA
- DrugBank DBSALT001814One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D003520 | Cyclophosphamide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 8N3DW7272P | CYCLOPHOSPHAMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 3002 | — | One source FDA |
| Wikidata | Q27106287 | cyclophosphamide hydrate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C405 | Cyclophosphamide | One source FDA |
| DrugBank | DBSALT001814 | — | One source Wikidata |
Also registered as cyclophosphamide anhydrous (UNII 6UXW23996M · RxNorm 1545988).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.